Specifically, due to existing experience combined with proven efficacy in other cancers and diseases, IL-6 and the immune checkpoint inhibitors (anti-PD-1/PD-L1 and anti-CTLA-4) may represent particularly good targets/therapies. The gene discussed is CTLA4; the disease is cancer.